Rationale for the use of mitoxantrone in multiple sclerosis

Journal of the Neurological Sciences

Volumn 223, Issue 1, 2004, Pages 35-39

  Edan, Gilles ^a   Morrissey, Sean ^a   Le Page, Emmanuelle ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Mitoxantrone; Multiple sclerosis; Relapsing remitting and secondary progressive MS

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FOLLOW UP; HEART DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LEUKEMIA; META ANALYSIS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 3142556057     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.04.017     Document Type: Article

References (35)

1. Rosenberg L.S., Carvlin M.J., Krugh T.R. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation. Biochemistry. 25:1986;1002-1008
2. Gilles E., Morissey S. Hawkins C.P., Wolinsky J.S. Mitoxantrone in principles of treatments in multiple sclerosis. 2000;131-146 Butterworth-Heinemann, Oxford, UK
3. Ridge S.C., Sloboda A.E., McReynolds R.A., et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin. Immunol. Immunopathol. 35:1985;35-42
4. Fidler J.M., Dejoy S.Q., Smith F.R., et al. Selective immunomodulation by the antineoplastic agent mitoxantrone: II. Non specific adherent suppressor cells derived from mitoxantrone-treated mice. J. Immunol. 136:1986;2747-2754
5. Fidler J.M., Dejoy S.Q., Gibbons J.R. Selective immunomodulation by the antineoplastic agent mitoxantrone: I. Suppression of B lymphocyte function. J. Immunol. 137:1986;727-732
6. Levin S., Saltzman A. Regional suppression therapy after onset and prevention of relapses in experimental allergic encephalomyelitis with mitoxantrone. J. Neuroimmunol. 13:1986;175-181
7. Lublin F.D., Lasava M., Viti C., Knobler R.L. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol. Immunopathol. 45:1987;122-128
8. Mauch E., Kornhuber H.H. Immunosuppressive therapy of multiple sclerosis with mitoxantrone. Fortschr. Neurol. Psychiatr. 61(12):1993 (Dec);410-417
9. Gbadamosi J., Buhmann C., Tessmer W., Moench A., Haag F., Heesen C. Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur. Neurol. 49(3):2003;137-141
10. Stuve O., Cree B.C., von Buedingen H.C., et al. Approved and future pharmacotherapy for multiple sclerosis. Neurologist. 8:2002;290-301
11. Weilbach F.X., Chan A., Toyka K.V., Gold R. Mitoxantrone-induced immunological changes in MS patients-ex vivo studies on proliferation and cell death of peripheral blood leukocytes. J. Neurol. 249(Suppl. 1):2002;113
12. Bellosillo B., Colomer D., Pons G., Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br. J. Haematol. 100(1):1998 (Jan);142-146
13. Neuhaus O., Wiendl H., Kieseier B.C., et al. Multiple Sclerosis: immunological effects of mitoxantrone in vitro reveal antigen-presenting cells as major targets. Eur. J. Neurol. 9(Suppl. 2):2002;130
14. Khoury S.J., Bharanidharan P., Bourcier K., et al. Immunologic effects of mitoxantrone therapy in patients with multiple sclerosis. Neurology. 59(Suppl. 3):2002;A245-A246
15. Hartung H.-P., Gonsette R., König N., et al. A phase 3 placebo-controlled, double blind, multicenter trial of mitoxantrone in progressive multiple sclerosis. Lancet. 360:2002;2018-2025
16. Krapf H., Morrissey S., Zenker O., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind European phase III multicenter study. MRI data 14th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, September 9-12:1998
17. Edan G., Miller D., Clanet M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicenter study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry. 62:1997;112-118
18. Ghalie R.G., Edan G., Laurent M., Mauch E., Eisenman S., Hartung H.P., et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology. 59(6):2002 (Sep 24);909-913
19. Ghalie R.G., Mauch E., Edan G., Hartung H.P., Gonsette R.E., Eisenmann S., et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. Scler. 8(5):2002 (Oct);441-445
20. Gbadamosi J., Munchau A., Weiller C., Schafer H. Severe heart failure in a young multiple sclerosis patient. J. Neurol. 250(2):2003 (Feb);241-242
21. Cattaneo C., Almici C., Borlenghi E., Motta M., Rossi G. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia. 17(5):2003 (May);985-986
22. Mogenet I., Simiand-Erdociain E., Canonge J.M., Pris J. Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis. Ann. Pharmacother. 37(5):2003 (May);747-748
23. Heesen C., Bruegmann M., Gbdamosi J., Koch E., Monch A., Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult. Scler. 9(2):2003 (Mar);213-214
24. Jaster J.H., Niell H.B., Dohan F.C. Jr., Smith T.W. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology. 60(8):2003 (Apr 22);1399-1400. [author reply 1400]
25. Brassat D., Recher C., Waubant E., Le Page E., Rigal-Huguet F., Laurent G., et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology. 59(6):2002 (Sep 24);954-955
26. Vicari A.M., Ciceri F., Folli F., Lanzi R., Colombo B., Comi G., et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia. 12(3):1998 (Mar);441-442
27. Edan G., Morrissey S., Hartung P. Use of mitoxantrone to treat multiple sclerosis. Cohen J.A., Rudick R.A. Multiple sclerosis therapeutics. 2003;403-426 Martin Dunitz
28. Edan G. the Mitoxantrone-Interferon Beta-1b European Multicenter Trial Group The role of intensive immunosuppression in multiple sclerosis: prospects of combination. Kappos L., Kesselring J., Radu E., Johnson K. Multiple sclerosis: tissue destruction and repair. 2001;285-290 Martin Dunitz
29. Gonsette R.E., Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology. 40(Suppl. 1):1990;261
30. Kappos L., Gold R., Künstler E., et al. Mitoxantrone in the treatment of rapidly progressive MS: a pilot study with serial gadolinium-enhanced MRI. Neurology. 49(Suppl. 1):1990;261
31. Mauch E., Kornhuber H.H., Krapf H., et al. Treatment of multiple sclerosis with mitoxantrone. Eur. Arch. Psch. Clin. Neurosc. 242:1992;96-102
32. Reess J., Eisenmann S., Mauch E., et al. Results of an open study with 75 MS patients treated with mitoxantrone. 14th Congress of the European Committee for treatment and research in multiple sclerosis. Mult. Scler. 4:1998;382
33. Noseworthy J.H., Hopkins M.B., Vandervoort M.K., et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology. 43:1993;1401-1406
34. Ruggero C., Marciano N. Mitoxantrone therapy of secondary progressive multiple sclerosis: pilot study. Neurology. 43(4 Suppl. 2):1993;S494
35. Mesaros S., Levic Z., Drulovic J. Treatment of multiple sclerosis with mitoxantrone. 14th Congress of the European Committee for treatment and research in multiple sclerosis. Multi. Scler. vol. 4:1998;387